Healthcare, Pharma & Life Sciences

Sectra Enters Brazil Market via Partnership with S&S Partners

Linköping – – September 29, 2026 -- Swedish medical imaging IT firm Sectra (STO: SECT B) has signed a partner agreement with S&S Partners to enter Brazil, Latin America's largest healthcare market, with an initial focus on its cloud-based enterprise imaging platform Sectra One Cloud.

Brazil's 7,100 hospitals drive shift from on-premise to cloud imaging

Brazil operates approximately 7,100 hospitals, with the private sector accounting for the majority of advanced imaging investment. Major private hospital groups are pushing the market away from on-premise capital purchases toward subscription-based cloud platforms, a shift Sectra says is already gaining momentum.

Torbjörn Kronander, President and CEO at Sectra, said the partnership with S&S Partners provides access to the relationships and local market knowledge required for entry into Brazil.

Lilly's Foundayo Outperforms Oral Semaglutide 25 mg in New Diabetes Data

Image
Lilly's Foundayo Outperforms Oral Semaglutide 25 mg in New Diabetes Data

Indianapolis – September 29, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its oral GLP-1 drug Foundayo (orforglipron) at 17.2 mg produced 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg over 52 weeks in adults with type 2 diabetes, based on an indirect treatment comparison presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan.

Indirect analysis draws on ACHIEVE-3 and PIONEER PLUS trial data

The comparison, covariate-adjusted for gender, age, baseline A1C and baseline weight, found weight-loss differences ranging from 1.5% to 2.4% and A1C reductions of 0.3% to 0.6% in favor of Foundayo 17.2 mg across multiple statistical methods. The 95% confidence interval for weight loss was -2.7% to -0.2%, and for A1C reduction was -0.6% to -0.1%.

Arthex Biotech Names Ex-IVERIC bio CEO Glenn Sblendorio Chairman

Image
Arthex Biotech Names Ex-IVERIC bio CEO Glenn Sblendorio Chairman

Valencia – – September 29, 2026 -- Arthex Biotech has appointed Glenn Sblendorio, former CEO of IVERIC bio, as Chairman of its Board of Directors as the clinical-stage RNA therapeutics company advances its lead program ATX-01 through Phase I/IIa trials for myotonic dystrophy type 1 (DM1).

Sblendorio brings three decades of biotech exit experience to Arthex's board

Sblendorio most recently led IVERIC bio, Inc. as CEO until its acquisition by Astellas Pharma, Inc. He previously served as President and Chief Financial Officer of The Medicines Company through its acquisition by Novartis, and as Executive Vice President and CFO of Eyetech Pharmaceuticals, Inc. until it was acquired by OSI Pharmaceuticals, Inc. Earlier in his career he was a Managing Director at MPM Capital Advisors.

Hengrui Licenses Oral GLP-1/GIP Drug to Novo in $2.6B Deal

Image
Hengrui Licenses Oral GLP-1/GIP Drug to Novo in $2.6B Deal

Shanghai – – September 29, 2026 -- Hengrui Pharma has licensed its investigational obesity and diabetes drug HRS-1596 to Novo Nordisk in a deal worth up to 2.6 billion US dollars, including a 300 million dollar upfront payment.

Novo secures global rights excluding Greater China

Under the agreement, Novo obtains exclusive rights to develop, manufacture and commercialise HRS-1596 worldwide, excluding the Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan Region. Hengrui Pharma retains eligibility for royalties on net sales of the drug within Novo's licensed territory, on top of the milestone-based payments tied to development, regulatory and commercial targets.

iRegene's NouvSight001 Cleared for RP Trials in US and China

Chengdu, China – September 29, 2026 -- iRegene Therapeutics has secured clinical trial clearances in both China and the United States for NouvSight001, an off-the-shelf cell therapy targeting retinitis pigmentosa (RP), a retinal disease affecting roughly 1.5 million people worldwide.

China's NMPA clears Phase I/III trial while FDA grants Phase I/II clearance with special exemption

China's National Medical Products Administration authorized a Phase I/III trial to assess safety, tolerability and preliminary efficacy of NouvSight001 in RP patients. The U.S. FDA separately cleared a Phase I/II trial for the same indication and granted a special exemption, building on the Orphan Drug Designation the agency awarded the program in 2024.

JOE Media Launches 'Listen to Jordic' Heart-Health Campaign on World Heart Day

Image
JOE Media Launches 'Listen to Jordic' Heart-Health Campaign on World Heart Day

London – September 29, 2026 -- JOE Media Group has launched a heart-health awareness campaign built around a Viking folk character named Jordic, using erectile dysfunction (ED) as an entry point to warn men about underlying cardiovascular disease risk.

Campaign ties ED symptoms to a two-to-five-year cardiovascular warning window

The 'Listen to Jordic' campaign, created by Havas Lynx UK for JOE Media Group, launched on World Heart Day exclusively on JOE.co.uk. Medical literature cited in the campaign indicates ED can precede cardiovascular symptoms by two to five years, offering a critical window for men to seek diagnosis.

Congress Passes ACT for ALS Reauthorization, Extends Programs to 2031

Image
Congress Passes ACT for ALS Reauthorization, Extends Programs to 2031

Los Angeles – – September 29, 2026 -- Congress has passed the Accelerating Access to Critical Therapies (ACT) for ALS Reauthorization Act of 2026 (H.R. 8205), sending the bipartisan bill to the President's desk just two days before the underlying program was set to expire on September 30, 2026.

Senate approval follows House passage, clearing the path for a presidential signature

The legislation cleared the U.S. House of Representatives before the Senate gave final approval, moving the bill to the President for signature. Once enacted, the law will extend core ACT for ALS programs through 2031, continuing federal support for ALS research infrastructure and expanded access to investigational therapies.

IASO Bio's In Vivo CAR-T IASO206 Hits 90% Response Rate in Myeloma Trial

Shanghai – September 29, 2026 -- IASO Biotechnology reported a 90% objective response rate and 90% minimal residual disease (MRD) negativity rate for its BCMA-targeted in vivo CAR-T therapy IASO206, generated via a single intravenous infusion without lymphodepleting chemotherapy, in first-in-human Phase 1 data presented as a late-breaking oral session (LBA-11) at the 2026 International Myeloma Society Annual Meeting.

AMP, Fuse Oncology Launch FuseRx Radiation Workflow Pilot in Syracuse

Image
AMP, Fuse Oncology Launch FuseRx Radiation Workflow Pilot in Syracuse

Syracuse – – September 29, 2026 -- Fuse Oncology and Associated Medical Professionals of NY (AMP), an affiliate of U.S. Urology Partners, a General Atlantic company, have launched a proof of concept for FuseRx, a clinical workflow platform for radiation oncology, at AMP's Center of Advanced Radiation Excellence in Syracuse.

Prostate cancer volume drives the test case

The American Cancer Society projects about 333,800 new U.S. prostate cancer cases in 2026, making it the most common cancer in American men after skin cancer. Roughly a third of men with localized disease receive radiation as primary treatment, a pathway that typically starts with a urologist diagnosis before crossing into separate oncology systems.

FDA Weighs Easing Tobacco Product Review Amid 7,500 Illegal Items

Image
FDA Weighs Easing Tobacco Product Review Amid 7,500 Illegal Items

Washington – September 29, 2026 -- The U.S. Food and Drug Administration announced plans to evaluate changes to its application framework for new tobacco products, including e-cigarettes and nicotine pouches, aiming to simplify the pathway for these products to reach the market.

Truth Initiative warns weakened review could undermine public health protections

Kathy Crosby, CEO and President of Truth Initiative, said any changes that reduce the scientific evidence required or diminish the review process would compromise the FDA's regulatory role. The law currently requires the agency to assess a product's components, ingredients, toxicological profile and health impact, alongside risks and benefits to the broader population, including youth and non-users.